Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG
H3K27M mutations resulting in epigenetic dysfunction are frequently observed in diffuse intrinsic pontine glioma (DIPGs), an incurable pediatric cancer. We conduct a CRISPR screen revealing that knockout of KDM1A encoding lysine-specific demethylase 1 (LSD1) sensitizes DIPG cells to histone deacetyl...
Hauptverfasser: | Anastas, JN, Zee, BM, Kalin, JH, Kim, M, Guo, R, Alexandrescu, S, Blanco, MA, Giera, S, Gillespie, SM, Das, J, Wu, M, Nocco, S, Bonal, DM, Nguyen, Q-D, Suva, ML, Bernstein, BE, Alani, R, Golub, TR, Cole, PA, Filbin, MG, Shi, Y |
---|---|
Format: | Journal article |
Sprache: | English |
Veröffentlicht: |
Cell Press
2019
|
Ähnliche Einträge
-
Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer.
von: Chandru Gajendran, et al.
Veröffentlicht: (2023-01-01) -
Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting
von: Kavya Parekh, et al.
Veröffentlicht: (2023-03-01) -
Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
von: Joshua P. Smalley, et al.
Veröffentlicht: (2020-09-01) -
ACVR1 mutations in DIPG: lessons learned from FOP.
von: Taylor, K, et al.
Veröffentlicht: (2014) -
DIPG in children - what can we learn from the past?
von: Magimairajan Issai eVanan, et al.
Veröffentlicht: (2015-10-01)